Eurand N.V.

In-line with its multi-product strategy, Forest Laboratories Inc. announced its intentions to acquire privately held Aptalis Holdings Inc. on Jan. 8. The $2.9 billion deal will delay new CEO B

The days before and after Christmas weren’t completely devoid of news. A pair of companies announced plans for initial public offerings, including an IPO for private equity-backed Aptalis. An antibact

Private equity firm TPG Capital is shopping its specialty drug company Aptalis Pharma, asking for more than $3 billion, but the price is too rich for some potential buyers, according to Reuters . The

Capitalism knows no holiday, but people need a break sometimes. The dog days of summer often slow the pace of biopharma deals, and 2013 is no exception. If you traded boardroom time for surfboard time